Research progress of severe acute respiratory syndrome, Middle East respiratory syndrome and corona virus disease 2019 treatment
FU Zhangfan, AI Jingwen
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China
Abstract：Severe acute respiratory syndrome (sever acute respiratory syndrome, SARS), Middle East respiratory syndrome (middle east respiratory syndrome, MERS), and new coronavirus pneumonia (corona virus disease 2019, COVID-19) have brought serious illnesses to people all over the world. Economic loss and mental injury, given that there are no new cases of SARS and little progress in research, this article focuses on the treatment of MERS and COVID-19. The treatments of MERS and COVID-19 are similar. Nucleoside analogs, lopinavir/ritonavir, neutralizing antibodies, glucocorticoids, and other potential therapies (new use of old drugs) have been used clinically. Due to the wide spread of COVID-19 and the large number of infected people, some new drugs have emerged, such as Remdesivir, REGN-COV2 antibody, LY-CoV555 antibody, etc., but the current effect is not good, and the clinical diagnosis and treatment plan has yet to be improved. This article reviews the research progress in the treatment of SARS, MERS and COVID-19, and provides a theoretical basis for further research on their treatment options, improving treatment effects, and reducing mortality.
傅掌璠，艾静文. 严重急性呼吸综合征、中东呼吸综合征和2019冠状病毒病治疗研究进展[J]. 微生物与感染, 2021, 16(3): 214-220.
FU Zhangfan, AI Jingwen. Research progress of severe acute respiratory syndrome, Middle East respiratory syndrome and corona virus disease 2019 treatment . JOURNAL OF MICROBES AND INFECTIONS, 2021, 16(3): 214-220.
2021, Vol. 16 
